Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

As the global weight-loss market explodes, drugmakers are now racing to solve a less visible problem: protecting muscle mass ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Several pharmaceutical companies are developing novel weight-loss drugs that focus not just on reducing fat but also on ...

Those on Wegovy alone lost 15.7% of their weight, with 71.8% coming from body fat — indicating more muscle was lost when the experimental drug wasn’t included in the regimen.